Evidence map›Paper›PMID 40680746›Full record

ArticleMolecular cell2025

The SWI/SNF-related protein SMARCA3 is a histone H3K23 ubiquitin ligase that regulates H3K9me3 in cancer.

Ifé Akano, Jakob M Hebert, Rochelle L Tiedemann, Qingzeng Gao, Yang Xiao, Nicholas A Prescott, Yanqing Liu, Kay See Tan, Ryan M Bastle, Aarthi Ramakrishnan and 6 more

Abstract read
In one paragraph

Article in Molecular cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ifé AkanoChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Jakob M HebertChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Tri-Institutional PhD Program in Chemical Biology, New York, NY, USA.
Rochelle L TiedemannDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Qingzeng GaoChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yang XiaoChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Tri-Institutional PhD Program in Chemical Biology, New York, NY, USA.
Nicholas A PrescottChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Tri-Institutional PhD Program in Chemical Biology, New York, NY, USA.
Yanqing LiuDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Kay See TanDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ryan M BastleDepartment of Neuroscience, Icahn School of Medicine, Mount Sinai, New York, NY, USA.
Aarthi RamakrishnanDepartment of Neuroscience, Icahn School of Medicine, Mount Sinai, New York, NY, USA.
Ian MazeDepartment of Neuroscience, Icahn School of Medicine, Mount Sinai, New York, NY, USA; Department of Pharmacological Sciences, Icahn School of Medicine, Mount Sinai, New York, NY, USA.
Simone SidoliDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA.
Richard P KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Karuna GaneshMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Scott B RothbartDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
Yael DavidChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA; Tri-Institutional PhD Program in Chemical Biology, New York, NY, USA; Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: davidshy@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Weill Cornell Initiative for Maximizing Student DevelopmentR25GM130494 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI CARRASCO, YAZMIN PAULINA, CESARMAN, ETHEL · 2019 to 2023
$2.4M
Investigating histone glycation as a new dynamic epigenetic markR35GM138386 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI DAVID-SHTERNBERG, YAEL E · 2020 to 2024
$2.2M
Molecular mechanisms of chromatin signaling and epigenetic regulationR35GM152184 · NIGMS · VAN ANDEL RESEARCH INSTITUTE · PI Scott Rothbart · 2024 to 2026
$1.6M
Tri-Institutional PhD Program in Chemical BiologyT32GM115327 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI TAN, DEREK S · 2015 to 2019
$741k
Application of intein-based chemical methods to directly manipulate neuronal histone modifications in rodent models of addictionR21DA044767 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DAVID-SHTERNBERG, YAEL E, MAZE, IAN S. · 2018 to 2019
$444k
NCI NIH HHS P30 CA008748NIDA NIH HHS R21 DA044767NIGMS NIH HHS R25 GM130494NIGMS NIH HHS R35 GM138386NIGMS NIH HHS R35 GM152184NIGMS NIH HHS T32 GM115327
6 · The paper itself

Abstract

Histone ubiquitination is a crucial post-translational modification (PTM) regulating chromatin function, yet many histone ubiquitination sites and the enzymes that control them remain poorly understood. Here, we identify SMARCA3, a SWI/SNF-related protein frequently downregulated in colorectal cancer (CRC), as an E3 ubiquitin ligase that targets histone H3 at lysine 23 (H3K23). We demonstrate that SMARCA3 histone ubiquitination activity is stimulated by the repressive H3K9me3 mark. Loss of SMARCA3 reduces both H3K23Ub and H3K9me3, increasing chromatin accessibility at promoters and enhancers enriched for pioneer transcription factor motifs. This chromatin "rewiring" alters the transcriptional landscape, driving upregulation of cancer-promoting genes. We validate this mechanism in CRC cell lines and patient-derived organoids, where SMARCA3 loss reduces H3K23Ub and H3K9me3. In xenograft mouse models, overexpression of wild-type SMARCA3, but not a RING domain mutant, suppresses tumor growth. Together, our findings define SMARCA3 as a key chromatin regulator contributing to CRC pathogenesis through epigenetic mechanisms.

Indexed as

Colorectal NeoplasmsHistonesTranscription FactorsUbiquitin-Protein LigasesAnimalsCell Line, TumorChromatinEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHCT116 CellsHumansLysineMicePromoter Regions, GeneticUbiquitinationChromatinHistonesLysineTranscription FactorsUbiquitin-Protein Ligasesepigenetics, histone, ubiquitination, methylation, chromatin, accessibility, cancer, RING, E3 ligase

Identifiers

PMID40680746
PMCPMC12327810

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.